Insmed Reports Q3 Revenue Beat Driven by Brensocatib Sales Despite GAAP EPS Miss
Insmed (INSM) reported third-quarter financial results characterized by a significant revenue beat and substantial year-over-year growth. The company recorded revenue of $524.4 million, exceeding market expectations by $24.92 million and representing a 269.3% increase compared to the same period last year. Despite the top-line strength, Insmed reported a GAAP earnings per share (EPS) of -$0.46, missing analyst estimates by $0.08. A primary driver of the revenue performance was brensocatib (brand name BRINSUPRI), which generated $400.1 million in revenue for the quarter, marking a 29% increase over the second quarter of 2026.
Tickers: $INSM
Topics: brensocatib earnings miss quarterly results revenue beat